Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
6.64
+0.18 (2.79%)
At close: May 28, 2026, 4:00 PM EDT
6.61
-0.03 (-0.45%)
After-hours: May 28, 2026, 4:58 PM EDT
Vanda Pharmaceuticals Revenue
Vanda Pharmaceuticals had revenue of $51.72M in the quarter ending March 31, 2026, with 3.35% growth. This brings the company's revenue in the last twelve months to $217.78M, up 8.16% year-over-year. In the year 2025, Vanda Pharmaceuticals had annual revenue of $216.11M with 8.72% growth.
Revenue (ttm)
$217.78M
Revenue Growth
+8.16%
P/S Ratio
1.85
Revenue / Employee
$408,597
Employees
533
Market Cap
399.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 216.11M | 17.33M | 8.72% |
| Dec 31, 2024 | 198.77M | 6.13M | 3.18% |
| Dec 31, 2023 | 192.64M | -61.74M | -24.27% |
| Dec 31, 2022 | 254.38M | -14.30M | -5.32% |
| Dec 31, 2021 | 268.68M | 20.51M | 8.27% |
| Dec 31, 2020 | 248.17M | 20.98M | 9.23% |
| Dec 31, 2019 | 227.19M | 34.07M | 17.64% |
| Dec 31, 2018 | 193.12M | 28.04M | 16.98% |
| Dec 31, 2017 | 165.08M | 19.07M | 13.06% |
| Dec 31, 2016 | 146.02M | 36.09M | 32.83% |
| Dec 31, 2015 | 109.93M | 59.77M | 119.16% |
| Dec 31, 2014 | 50.16M | 16.28M | 48.05% |
| Dec 31, 2013 | 33.88M | 1.15M | 3.52% |
| Dec 31, 2012 | 32.73M | 1.46M | 4.66% |
| Dec 31, 2011 | 31.27M | -4.44M | -12.43% |
| Dec 31, 2010 | 35.71M | 31.16M | 685.16% |
| Dec 31, 2009 | 4.55M | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 227.18M |
| Verastem | 49.59M |
| OmniAb | 28.94M |
| X4 Pharmaceuticals | 9.01M |
| Artiva Biotherapeutics | 251.00K |
| Lyell Immunopharma | 31.00K |
VNDA News
- 1 day ago - Vanda Pharmaceuticals’ imsidolimab granted orphan drug designation in Japan - TheFly
- 1 day ago - Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis - PRNewsWire
- 9 days ago - Vanda Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts
- 10 days ago - Vanda Pharmaceuticals Slides: Corporate presentation - Filings
- 17 days ago - Vanda Pharmaceuticals price target lowered to $21 from $24 at H.C. Wainwright - TheFly
- 20 days ago - Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences - PRNewsWire
- 21 days ago - Vanda Pharmaceuticals reports Q1 EPS (82c) vs. (50c) last year - TheFly
- 21 days ago - Vanda Pharmaceuticals raises FY26 revenue view to $240M-$290M from $230-$260M - TheFly